Seasonal Influenza Vaccines Analysis & Forecast in Asia-Pacific Markets to 2028 - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Feb 3, 2020--
The “Seasonal Influenza Vaccines: Forecast in Asia-Pacific Markets to 2028” report has been added to ResearchAndMarkets.com’s offering.
Seasonal influenza is a viral infection that occurs annually in the winter months from December to March/April in the Northern Hemisphere and from May to August/September in the Southern Hemisphere, though most of India follows Southern Hemisphere seasonality. Two types of influenza virus, type A and B, are responsible for the majority of seasonal influenza infections in humans, and due to frequent virus mutations annual vaccination is recommended. The WHO estimates three to five million cases of severe seasonal influenza infections and 290,000 to 650,000 influenza-related respiratory deaths, most of them in the elderly population. Therefore, many countries recommend annual immunization against seasonal influenza, especially for high-risk groups such as young children, pregnant women, elderly people, and people with chronic diseases, but seasonal influenza is not on the national immunization schedule in China and India.
Immunization provides the best protection against the influenza virus and vaccines have been available for decades with a recent switch from trivalent to quadrivalent vaccines that protect against each two influenza type A and two B strains. Traditionally, seasonal influenza vaccines have been produced in eggs, but a slow manufacturing process and viral egg-adaptations have led to a push for cell-based and recombinant vaccine production methods in recent years.
During the 10-year forecast period, there are nine pipeline products that are on track to launch, driving a forecast growth in the 3GM from $914M in 2018 to $1.05B in 2028, which represents a CAGR of 1.4%.
The late stage pipeline for seasonal influenza vaccines in the 3GM includes the first quadrivalent seasonal influenza vaccines in China from Sinovac, Chongqing Zhifei, and Wuhan, as well as a quadrivalent formulation of Fluad. Quadrivalent live-attenuated vaccines will launch in India (from the Serum Institute) and Japan (AstraZeneca’s FluMist, licensed by Daiichi Sankyo). Furthermore, two new inactivated quadrivalent vaccines from Biken and Denka Seiken will launch during the forecast period, as well as a novel plant-based influenza vaccine in Japan.
Medicago’s MDG-2271 will be the first non-egg-based vaccine to launch in the 3GM, addressing the urgent unmet need of influenza vaccine efficacy by shortening production time and minimizing virus mutations.
Another major unmet need in the 3GM is a high vaccination rate and the lack of government support for seasonal influenza immunization in China and India, resulting in vaccination rates around 2%. Vaccination rates in Japan are projected to remain low due to vaccine hesitancy and skepticism.
Key Questions Answered -
Reasons to buy
The report will enable you to -
Key Topics Covered:
1 Seasonal Influenza Vaccines: Executive Summary
1.1 Modest Growth Expected for the Seasonal Influenza Vaccine APAC Market over the Forecast Period from 2018-2028
1.2 Transition from Trivalent to Quadrivalent Influenza Vaccines in China and India, Launch of Specialized Vaccines in Japan
1.3 Higher Seasonal Influenza Vaccination Rates and Better Vaccine Efficacy Are Major Unmet Needs
1.4 Quadrivalent Inactivated and Live-Attenuated Influenza Vaccines Will Launch in China and India, Plant-Based Vaccine in Japan
1.5 What Do Physicians Think?
2.2 Related Reports
2.3 Upcoming Related Reports
3 Disease Overview
3.1 Etiology and Pathophysiology
4.1 Disease Background
4.2 Risk Factors and Comorbidities
4.3 Global and Historical Trends
4.4 Forecast Methodology
4.5 Epidemiological Forecast for Disease Seasonal Influenza (2018-2028)
5 Disease Management in APAC
5.1 Diagnosis and Treatment Overview
6 Competitive Assessment
7 Unmet Needs and Opportunity Assessment in APAC
7.2 Immunization Programs Including the Elderly and Children
7.3 Enhanced Vaccine Efficacy in High-Risk Groups
7.4 Public Opinion of Seasonal Influenza Vaccines: Awareness, Hesitancy, and Skepticism
7.5 Vaccines Leveraging Improved Manufacturing Technologies and Featuring Broader Influenza Strain Coverage
8 Pipeline Assessment in APAC
8.2 Promising Drugs in Clinical Development
9 Current and Future Players in APAC
9.2 Trends in Corporate Strategy
9.3 Company Portfolio Assessment
10 Market Outlook in APAC
10.1 Global Markets
For more information about this report visit https://www.researchandmarkets.com/r/ytpmq5
View source version on businesswire.com:https://www.businesswire.com/news/home/20200203005593/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
KEYWORD: ASIA PACIFIC
INDUSTRY KEYWORD: INFECTIOUS DISEASES PHARMACEUTICAL HEALTH
SOURCE: Research and Markets
Copyright Business Wire 2020.
PUB: 02/03/2020 11:24 AM/DISC: 02/03/2020 11:24 AM